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Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression
of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer
drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are
in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials
have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions.
Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here
we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting
angiogenesis for treatment of these rare cancers.
1.Introduction
The generation of new capillaries from preexisting blood
vessels is termed angiogenesis [1]. Angiogenesis functions
as the result of a dynamic balance between proangiogenic
factors, for example, vascular endothelial growth factor
(VEGF) and platelet-derived growth factor (PDGF), and
factors that inhibit angiogenesis such as thrombospondin-1
and angiostatin [2]. The process of regulated angiogenesis
occurs during embryogenesis, the menstrual cycle, wound
healing, and pathologic states. Unregulated angiogenesis
may lead to numerous diseases and is thought to play an
indispensable role in solid tumor growth and metastasis.
Numerousinvestigationsontumordevelopmenthaveshown
that an alteration in the blood supply can noticeably
inﬂuence the tumor growth and its metastasis [2]. As with
normal tissue, the growing tumor requires an extensive
network of capillaries to provide the necessary nutrients and
oxygen. Moreover, the new intratumoral blood vessels oﬀer
a way for tumor cells to enter the circulation and metastasize
to distant organs. In this context, angiogenesis plays a crucial
role in facilitating the growth of the primary tumor and
generating metastasis. However, in the early 1900s it was
recognized that “vessels showed changes, such as defective
coatings, dilation, obliteration, and thrombosis” [3, 4] (cited
in [5]). Extensive research in this area has indicated that
the eﬀective inhibition of blood vessel formation can result
in tumor regression, although the predominant eﬀect is the
slowing of tumor growth. However, targeting the stromal
elements of the tumor, rather than focusing on the cancer
cells exclusively, represents a major shift in emphasis in
cancer research. Unfortunately, due to the heterogeneity
of the angiogenesic process within diverse neoplasms, it is
diﬃcult to generalize research ﬁndings to all tumor types.
Here we have focused on the available data on angiogenesis
andtargetingangiogenesisasitpertainstopediatricsarcoma.
2. Angiogenesis inChildhood Sarcomas
Sarcomas present a great challenge for cancer therapy
because they comprise a relatively uncommon group of
diseases. Sarcomas encompass many diseases, not simply
a representation of a single entity of mesenchymal origin.
Pediatric soft tissue sarcomas are a group of malignant
tumors that originate from primitive mesenchymal tissue
and account for 7% of all childhood tumors [6]. As a result2 Sarcoma
of their diverse biology, therapeutics for pediatric sarcomas
will ultimately be tailored to the speciﬁc tissue type [7–10].
Established chemotherapy regimens for advanced or
metastatic sarcoma generally have low 5-year event-free
survival, and current therapies have substantial toxicity.
Resistance often arises quickly, making advanced sarcoma
an acceptable target for alternative treatment approaches.
Antiangiogenic therapies have a number of potential advan-
tages including decreased resistance, fewer side eﬀects, and a
broad spectrum of activity. Human sarcomas express a num-
ber of proangiogenic factors that may represent potential
therapeutic targets, with VEGF being the best characterized.
Inhibitors of angiogenesis have demonstrated antitumor
activityinanimalmodelsofchildhoodsarcomas,andclinical
trials are in the early stages, although promising results are
already being seen. Antiangiogenic and immunomodulatory
therapies are gaining momentum in the pediatric arena and,
when tested in combination with traditional cytotoxic agents
for recurrent and high-risk primary pediatric sarcomas, may
lead to more eﬀective and tolerable therapies [11].
An example of potential antiangiogenic therapeutic tar-
gets can be observed in rhabdomyosarcoma (RMS) cell lines.
These cells secrete VEGF [12, 13] as well as other angiogenic
factors such as basic ﬁbroblastic growth factor (bFGF) and
interleukin8[14]aswellasotherpotentialangiogenicfactors
[15].InmostRMScelllinesVEGFstimulatesproliferationor
activatesthePI3K/Aktpathway[12,13],henceactingasboth
an autocrine growth factor and a paracrine factor involved in
angiogenesis.
Microvessel density (MVD) has also been found to be
a prognostic factor in the response to therapy and survival
in several adult carcinomas [16–19]. Observations from
diﬀerent studies suggest that MVD in soft tissue sarcomas
(STS) was not associated with histological type, grading,
metastatic behavior, or survival [20–23]. Rather, tissue levels
of VEGF were associated with local recurrence and survival
[20]. In contrast MVD was correlated with survival in adult
soft tissue sarcoma of the extremities [24]. Tomlinson et al.
describe a diﬀerent pattern of angiogenesis in STS compared
to breast carcinoma. In breast cancer, the capillaries were
clustered in bursts within the stroma of the tumor, while
the sarcoma capillaries were homogeneously distributed
throughout the tumor stroma. They credit this diﬀerence to
the greater number of activated ﬁbroblasts in carcinomas,
with their own gradients of angiogenic factors in the
tissues. This aspect has been studied in carcinosarcoma,
which contains both tumor types. In accordance with the
ﬁndings of Tomlinson et al. [22], a study by Yoshida et al.
describes a signiﬁcantly higher MVD in the carcinomatous
areas of the tumor than that found in the sarcomatous
parts [25]. However, the consequences of this in terms of
antiangiogenesis therapy of STS are not yet clear.
3. AngiogenicFactorsSecretedby
Childhood Sarcomas
As noted above, balance between proangiogenic and antian-
giogenic factors, with the involvement of diﬀerent cells and
stimulating factors, regulates the process of angiogenesis.
Some of the cells engaged are endothelial cells (EC), lym-
phocytes, macrophages, and mast cells. Vascular endothelial
growth factor and ﬁbroblast growth factor (FGF) are two of
the major factors involved in this process. These cells and
stimulating factors play diﬀerent and important roles during
tumor angiogenesis. From the more than 20 proangiogenic
and antiangiogenic agents identiﬁed, VEGF and bFGF have
been established as the two most potent positive regulators
of angiogenesis [26–28]. However, other cytokines, such
as interleukin-1 receptor α (IL-1R), IL-6, and IL-8, tumor
growth factor-α (TGF-α), TGF-β, tumor necrosis factor-
α (TNF-α), hepatocyte growth factor (HGF), leptin, and
platelet-derived growth factor (PDGF), have been reported
tobeinvolvedaswell,thoughtheirroleshavenotalwaysbeen
clearly deﬁned [28–34].
As previously described, tumor cells require nutrients
and oxygen to overcome hypoxia and starvation. When
a condition such as hypoxia is present within the tumor
tissue, the tumor cells are stimulated to promote the
secretion of various angiogenic factors for the induction of
angiogenesis [35]. Of clinical signiﬁcance, the pretherapeutic
serum VEGF levels were found to be signiﬁcantly higher
in patients with osteosarcoma who relapsed during the
ﬁrst year of treatment, providing the basis to establish
further antiangiogenic therapy to target patients at high
risk of angiogenesis-dependent relapse of osteosarcoma [36].
However, the prognostic signiﬁcance of angiogenic factors in
childhood sarcoma remains ambiguous.
4. Antibody-Based AntiangiogenicTherapy
Bevacizumab (Avastin; Genentech Inc.), a humanized anti-
body against that binds VEGF [37], must be regarded as the
gold standard against which other antiangiogenic treatments
are compared. Bevacizumab speciﬁcally binds to VEGF-A
and its isoforms to counteract the proangiogenic eﬀects
of VEGF, allowing for the normalization of the tumor
vasculature [38]. It is approved for several adult indications
and currently being evaluated in combination treatment
regimensforvariousadultmalignancies[39–41].Theclinical
experience with bevacizumab in pediatric patients is limited.
Ar e p o r tb yB e n e s c he ta l .[ 42] indicated that bevacizumab
has activity in pediatric malignancies, but large multicenter
trials are needed to quickly assess the clinical value of
this drug in childhood malignancies. Ongoing trials include
evaluation against osteosarcoma and Malignant Fibrous
Histiocytoma (MFH) of bone. Although bevacizumab is not
without toxicity, pediatric trials combining this agent with
conventional chemotherapy regimens are in development.
5.SmallMoleculeInhibitorsof
Angiogenesis inSarcomas
Therearemultiplehumoralfactorsinvolvedintheregulation
of both normal and abnormal angiogenesis. From the
perspective of small molecule development VEGF signaling
has been the predominant target, as VEGF was found to beSarcoma 3
overexpressed in various malignancies [43, 44]. Preclinical
studies have evaluated a wide range of strategies and
compounds to inhibit angiogenesis in laboratory models. Of
these agents, tyrosine kinase inhibitors (TKIs) have gained
attention as a means of targeted treatment for a wide range
of human cancers. At least 90 tyrosine kinase genes have
been identiﬁed in human cancers [45], and several TKIs
inhibitors are now approved for use in the treatment of
cancer in the United States. However, only few of these
have been adequately evaluated in childhood sarcoma.
However “selective,” small molecule inhibitors usually do
not inhibit only a single kinase, but result in the targeting
multiple signaling pathways. The “multitargeted” TKIs have,
in general, shown the most activity against solid tumors.
Of the small molecule inhibitors with oral bioavailability,
sorafenib (Nexavar; Bayer Pharmaceuticals) and sunitinib
(Sutent;PﬁzerInc.)actonmultipleintracellularandreceptor
protein kinases (e.g., VEGF receptors, PDGFR, FLT3, RET,
BRAF, KIT) that are components of signaling pathways
controlling tumor growth and angiogenesis. Both of these
agents have similar drug proﬁles and overlapping targets
[46] and are currently approved by the U.S. Food and Drug
Administration for the treatment of advanced renal cell
carcinoma (RCC) in adults [47]. In a study conducted by the
Pediatric Preclinical Testing Program (PPTP), sorafenib was
demonstrated to be an eﬀective inhibitor of tumor growth
across multiple histotypes in vivo [48]. Currently, sorafenib
isbeingevaluatedinhigh-gradeosteosarcoma.Sunitinibalso
showed signiﬁcant tumor growth inhibition against most
of the PPTP’s solid tumor panels, but little activity against
the neuroblastoma and ALL panels. The antitumor activity
of sunitinib was manifested as primarily a delay in tumor
growth, consistent with an antiangiogenic eﬀect against
many of the pediatric preclinical models evaluated [49].
Cediranib (Recentin; AZD2171; Astrazeneca Inc.),
another small molecule with oral bioavailability, is an
indole-ether quinazoline which inhibits the tyrosine kinase
activity of the vascular endothelial growth factor receptors
VEGFR-1 (Flt-1), VEGFR-2 (KDR), VEGFR-3 (Flt-4),
and c-KIT. Cediranib was previously shown to prevent
both physiologic and pathologic angiogenesis in vivo [50],
inhibiting the growth of a number of diﬀerent pediatric
human tumor xenografts [50, 51]. Currently in phase II/III
clinical development, early clinical studies have shown
encouraging antitumor activity in patients with a broad
range of solid tumors, as well as time-dependent and dose-
dependent changes in pharmacodynamic markers [52]. The
results from a recently completed clinical trial have shown
that the daily administration of cediranib to glioblastoma
patients resulted in a rapid and prolonged normalization of
the tumor vasculature which subsequently led to a reduction
in tumor-associated edema [53]. Promising preliminary
results have also been reported for treatment of alveolar
soft part sarcoma (ASPS), a tumor that responds poorly
to conventional chemotherapeutic regimens [54]. Of seven
patients with ASPS four had partial responses and two either
marginal response or stable disease [55].
Rapamycinanditsderivatives(temsirolimus,everolimus,
radiforolimus) selectively inhibit a serine/threonine kinase
mTOR (mammalian target of rapamycin) that controls
translation and transcription. These are immunosuppressive
macrocyclic lactone antibiotics that block mTOR function
and produce an antiproliferative eﬀect in a variety of malig-
nancies. Rapamycin has demonstrated broad antitumor
activity against the pediatric cancers in PPTP’s in vivo tumor
panels,withnoteworthyactivityinselectedsarcomaandALL
xenografts [56]. Initial reports have suggested that the eﬀects
of rapamycin may be related to its inhibitory action against
the endothelial cells, eﬀectively blocking tumor angiogenesis
[57, 58]. Rapamycin has the potential to disrupt the action
of vascular endothelial growth factor (VEGF) in the growth
plate and interfere with insulin-like growth factor I (IGF-I)
signaling[59].Rapalogshavebeenshowntoinhibithypoxia-
induced induction of hypoxia inducible factor-1α (HIF-1α),
the major transcription factor that reprograms cells under
hypoxic stress and induces VEGF transcription. These new
ﬁndings suggest potential beneﬁts of including rapamycin
as an antiangiogenic agent in the treatment regimens of
pediatric cancer patients. However, at least in some sarcoma
xenograft models, rapamycin treatment stimulated tumor-
associated VEGF, although the mechanism for this is poorly
understood [60].
6. Role of IGFsin Childhood Sarcomas
It is becoming increasingly evident that the Type-1 insulin-
like growth factor (IGF-1R) and its ligands (IGF-1, IGF-2)
play roles in both tumor cell proliferation and survival, and
proliferation of vascular endothelial cells. IGFs are balanced
by insulin-like growth factor-binding proteins (IGFBPs).
IGFBPs comprise a family of secreted proteins that modulate
thebioavailability ofinsulin-like growthfactors(IGFs)inthe
IGF-I/IGF-I receptor (IGF-IR) signaling axis. IGF binding
protein-3 (IGFBP-3) is emerging as a key regulator of cell
growth and apoptosis, both as an IGF antagonist and as an
independent molecule, which plays roles in the proliferation
and migration of HUVEC cells. IGFBP-3 expression is gen-
erally inhibited in Ewing’s sarcoma cells, as a consequence of
EWS/FLI1 expression. Exposure of neoplastic cells to IGFBP-
3 inhibits their growth, migratory, invasive, angiogenic, and
metastatic potential, therefore demonstrating the protein
as a molecule of therapeutic relevance to be considered
in the treatment of patients with Ewing sarcoma [61]. In
contrast, the IGFBP-3-induced endothelial cell motility and
migration may suggest a direct role for this binding protein
in promoting angiogenesis [62, 63]. The functional role of
IGFBP-5 in retarding angiogenesis has also been described.
Tumor growth and tumor vascularity were decreased in
the presence of IGFBP-5 expression in a xenograft model
of human ovarian cancer [64]. Insulin-like growth factor-
binding protein-7 (IGFBP7) is a secreted 31-kDa protein,
which is also called as IGFBP-related protein 1 (IGFBP-rP1)
[65]. IGBP7 shares high homology with the IGFBPs and
binds IGF-I and insulin, but its binding aﬃnity for IGF-I is
lower than those of IGFBPs 1 to 6 [66]. IGFBP7 is highly
expressed in the blood vessels of various human cancer
tissues, suggesting that it might suppress the pathological4 Sarcoma
action of VEGF, which is mainly derived from tumor cells.
Data suggest that IGFBP7 in the blood vessels of tumors
may lead to a unique tumor vasculature with characteristics
signiﬁcantly diﬀerent from those of normal vasculature.
The inhibitory eﬀect of IGFBP7 on tumorigenicity might
be partially mediated by its ability to suppress VEGF-
stimulated angiogenesis, although there is so far no direct
evidence to explain if IGFBP7 aﬀects tumor blood vessels.
The use of IGFBPs to limit IGF-1R signaling has been
proposed as a therapeutic approach. Gallicchio et al. [67]
reported that IGFBP-6 signiﬁcantly inhibited monolayer RD
and Rh-30 cell proliferation in a dose-dependent manner.
Furthermore, the overexpression of IGFBP-6 resulted in a
74–88% reduction in Rh-30 tumor size in vivo after 18 days,
showing that IGFBP-6 can be a potent antitumor agent.
For approximately two decades, the insulin-like growth
factor (IGF) has been implicated in the pathogenesis of
numerous pediatric malignancies, including osteosarcoma,
Ewing sarcoma, and rhabdomyosarcoma (RMS). The role of
IGF-1R signaling in the pathogenesis of RMS and its role
in preventing apoptosis induced by a multitude of cellular
stresses, including cytotoxic drugs, radiation, and hypoxia
[68], indicate that targeting this pathway may have consider-
able utility in the therapy of RMS. IGF-II is also involved in
normal muscle growth, and Northern blot analysis of tumor
biopsy specimens from patients with both alveolar and
embryonalrhabdomyosarcomahasdemonstratedhighlevels
ofIGF-IImRNAexpression[69].Thissuggeststhepossibility
that upregulation of IGF-II plays a role in the unregulated
growth of these tumors. Support for this hypothesis came
from the ﬁnding that RMS cell lines also secrete IGF-II,
which then binds to IGF-1R, resulting in autocrine growth
proliferation and increased cell motility [70].
Ewing’s sarcoma, peripheral primitive neuroectodermal
tumor, and Askin tumor form a group of tumors collectively
termed Ewing’s sarcoma family of tumors (ESFT). These
tumors are characterized by speciﬁc chromosomal transloca-
tions that cause the N-terminus of EWS to be fused to the C-
terminus of one member of the ETS family of transcription
factors, most commonly FLI1 [71]. Expression of the fusion
producthasbeenimplicatedinoncogenesis.TheroleofIGF-
1R signaling in ESFT has undergone extensive evaluation.
EFST cell lines express IGF-1R and secrete IGF-I, and
IGF-1R-blocking antibodies interrupt this autocrine loop
[72, 73].
T h ei m p o r t a n c eo ft h eI G Fa x i st oc e l lg r o w t ha n d
diﬀerentiation in both normal tissues and cancer and the
aforementioned association of osteosarcoma with periods
of rapid bone growth help to explain the current focus for
therapies targeting the type 1 IGF receptor (IGF-1R). The
peak incidence of osteosarcoma occurs during adolescence,
corresponding to both the growth spurt and peak concentra-
tions of circulating GH and IGF-1 [74]. This epidemiological
correlation has led to the hypothesis that high levels of IGF-1
play an important role in the pathogenesis of osteosarcoma.
This hypothesis is supported by a host of preclinical data:
(a) osteosarcoma cells express functional IGF-1R on the cell
surface, (b) exogenous IGF-1 stimulates osteosarcoma cells
to proliferate, (c) IGF-1-dependent growth can be inhibited
using monoclonal antibodies or antisense oligonucleotides
against IGF-1R [75], (d) the treatment of mice with a
humanized anti-IGF-1R antibody resulted in tumor regres-
sion in two osteosarcoma xenograft models [76], and (e)
the majority of osteosarcoma patient samples express IGF
ligands, and 45% express IGF-1R [77].
7. Role of IGF’s in Angiogenesis
As described above, IGFBPs have both antitumor and
antiangiogenic properties, although whether these two char-
acteristics are linked remains to be demonstrated. However,
thesedatasuggestthatantibodiesthatpreventligandbinding
to the IGF-1R, or ligand binding antibodies per se,m a y
have therapeutic utility in childhood sarcomas. Phase-1
or -2 clinical trials with eight fully human antibodies, or
humanizedantibodies,thattargetIGF-1Randpreventligand
binding have been reported [78]. For commercial reasons
two agents (SCH717454 and R1507) are not being developed
further. These antibodies show speciﬁcity for the IGF-IR
although they may also inhibit chimeric receptors formed
through heterodimerization with the insulin receptor. In
preclinical models of childhood cancers, the prototypical
anti-IGF-1R antibody, α-IR3, mediated downregulation of
IGF-IR, signiﬁcantly retarded the growth of several cell lines
in vitro [70], and inhibited the growth of pediatric cancer
xenografts [79]. SCH717454 signiﬁcantly inhibits growth
of RMS xenografts and induces regressions in several sar-
coma histotypes, notably osteosarcoma and Ewing sarcoma
[80]. R1507 was found to inhibit growth of osteosarcoma
xenografts [81]. In some in vivo models of Ewing sarcoma
and osteosarcoma targeting IGF-1R with CP751871 dramat-
ically suppressed VEGF transcription and reduced tumor-
associatedVEGFwithin24hoursofantibody administration
[60]. Furthermore, SCH717454 treatment markedly reduced
blood vessel formation in tumor xenografts, showing that
the in vivo activity is derived not only from its inhibition
of tumor cell proliferation, but also from its angiogenesis
activity [82].
The molecular characterization of these sensitive mod-
els where IGF-IR signaling appears to be critical could
identify subsets of tumors that have become “addicted” to
this pathway [83]. In other preclinical models, blocking
IGF-IR signaling results in signiﬁcant retardation of tumor
growth, although in a clinical setting this response would
still be scored as progressive disease. In these models with
intermediate sensitivity, such as RMS, combinations of
signaling inhibitors would be a potentially more eﬀective
antitumor therapy. One strategy that is being evaluated
in preclinical models is the combination of the mTOR
inhibitor, rapamycin, with IGF-1R inhibitors. The basis for
this combination is that inhibition of mTOR upregulates
IGF-1R signaling through stabilization of IRS-1 [84]a n d
IGF-1R signaling blocks rapamycin-induced apoptosis [85,
86]. One IGF-1R inhibitor, CP751871, caused complete IGF-
1R downregulation, suppressed AKT phosphorylation, and
dramatically suppressed tumor-derived vascular endothelialSarcoma 5
growth factor (VEGF) in some sarcoma xenografts. Treat-
mentwithrapamycinalonedidnotmarkedlysuppressVEGF
in tumors and synergized only in those tumor lines where
VEGF was inhibited by CP751871. This data suggests a
model in which the blockade of IGF-1R suppresses tumor-
derived VEGF to a level where rapamycin can eﬀectively
suppress the response in vascular endothelial cells [60].
Exactly how rapamycin blocks the response to VEGF in
vascular endothelial cells is not clear. However, recent
studies show that SCH717454 potently inhibits VEGF-
induced proliferation of HUVECs, indicating that IGF-
1R-mediated signaling is essential for vascular endothelial
cell proliferation (H. K. Bid, PJH, unpublished data). As
discussed above, rapamycin has been shown to potently
inhibit IGF-1-stimulated proliferation of tumor cells [87].
Alternative approaches to inhibiting IGF-1R signaling
comprise the development of ligand binding antibodies.
Targeting the receptor ligand rather than the receptor per se
has proven to be a valuable approach for the antiangiogenic
antibody (bevacizumab), and high-aﬃnity, fully human
antibodies have been developed against IGF-II [88].
Phase I and phase II trials using many of these IGF-
1R-targeted antibodies are currently in progress. To date,
there have been very few serious side eﬀects resulting from
this treatment. Hyperglycemia, when present, has been mild
and has only been seen in some of the antibodies tested
[89–93]. Because of the important role of the IGF pathway
in normal growth, there is concern about the impact of
IGF blockade in patients who are still growing. Details of
recent clinical trials are provided in Table 1. Unfortunately,
in these tumor types, many of the patients are teenagers or
younger children. The hypothetical concern of disrupting
normal growth must be taken under consideration, but also
weighed against the pressing issue of tumor progression. The
only way to assess the impact of IGF-1R-directed therapy
on normal growth is to monitor young patients who have
been treated with the antibody for a prolonged period over
the course of their growth. On the positive side, this would
indicate that the patient is responding or the disease is not
progressing, on therapy. Data have not emerged suggesting
that one antibody is more eﬀective than another. However,
slight diﬀerences in regards to whether the antibody is fully
human or humanized, their relative aﬃnity to the IGF-1R
and IR, and their ability to block the binding of either IGF-I
or IGF-II ligand have not resulted in markedly diﬀerent side
eﬀects or tolerability, but could lead to diﬀerences in clinical
activity.
8. Vasculogenesis inChildhood Sarcoma
Vasculogenesis and angiogenesis are the fundamental pro-
cesses by which new blood vessels are formed [35, 94,
95]. Vasculogenesis is deﬁned as the diﬀerentiation of
precursor cells (angioblasts) into endothelial cells and the
de novo formation of a primitive vascular network, whereas
angiogenesis is deﬁned as the growth of new capillaries
from preexisting blood vessels [35]. Several studies have
now been published that suggest that not only angiogenesis
but also vasculogenesis may be involved during postnatal
life in situations that require an expanded vessel network.
Solid tumors require development and expansion of a
vascular network for nourishment to support their growth.
Angiogenesis was initially regarded as the sole mechanism by
whichtumorvesselsexpand.However,othermechanismsare
also involved in the expansion of the tumor vascular network
such as vasculogenesis.
Both angiogenesis and vasculogenesis contribute to the
formation and expansion of the tumor vasculature that
supports the growth of Ewing’s sarcoma [96]. Data from
Lee et al., 2006 [96] support the same hypothesis because
they demonstrated that not only local endothelial cells
but also bone marrow (BM)-derived cells are involved
in the generation of the new tumor vasculature during
the growth of Ewing’s sarcoma. Several cytokines, such as
Granulocyte Colony-Stimulating Factor, Placental Growth
Factor, and Stromal cell-derived Factor-1 (SDF-1), have been
shown to induce BM stem/progenitor cell mobilization and
chemotaxis. With respect to tumor growth, both stimulatory
andinhibitoryrolesofSDF-1havebeenreported.Disruption
of the SDF-1/CXCR4 axis was found to inhibit tumor
growth, microvessel density, and intratumoral blood ﬂow
without aﬀecting VEGF levels [97]. Reddy et al., 2008 [98]
suggestthattheeﬀectsofSDF-1ontumorneovascularization
include augmented chemotaxis of BM cells, retainment of
BM-derived pericytes in close association with the vessel
endothelial lining, enhanced overall pericyte coverage of
tumor neovessels, and remodeling of vascular endothelium
into larger, functional structures. All these processes together
support the growth of Ewing’s tumors, with distinctly
reduced VEGF165. Overall these reports suggest that BM-
derived cells play a critical role in the expansion of the
Ewing’s tumor vasculature, and that vasculogenesis may be
one of the mechanism by which tumors can evade the
eﬀects of antiangiogenic therapy targeted at VEGF. Similarly,
vasculogenesis is likely in other sarcomas. With inhibitors
of CXCR4 in development, the therapeutic potential for
simultaneous inhibition of angiogenesis and vasculogenesis
may be tested.
9.SummaryandPerspective
Growth of sarcoma, like other solid tumors, is dependent
on angiogenesis and vasculogenesis, hence understanding
the basic mechanisms and factors that inﬂuencing these
processes has the potential to reveal additional targets for
intervention. To date, the eﬀectiveness of angiogenesis-
directed treatments has not been particularly striking. In
adults these agents extend event-free survival by weeks or
months in the majority of malignancies. Thus, the role
of such therapeutic approaches must be considered in the
context of childhood cancer where the intent is cure. One
can see the value of essentially cytostatic therapy in the
context of young children where delay in tumor progression
may be of value in delaying radiation treatment (particularly
in CNS malignancies). However, is it realistic to anticipate
thatantiangiogenic treatmentswillconvertchildhood cancer6 Sarcoma
Table 1: Summary of select recent clinical studies for sarcoma.
Compounds/Agents in Clinical trials Tumor type Identiﬁer
A Phase II trial of dasatinib Advanced sarcoma SARC009
A Phase II trial of R1507, a recombinant
human monoclonal antibody to the
insulin-like growth factor-1 receptor
Recurrent or refractory ewing’s sarcoma,
osteosarcoma, synovial sarcoma,
rhabdomyosarcoma, and other sarcomas
SARC011
A randomized, double-blinded,
placebo-controlled, multiinstitutional, phase
II.5 study of AZD0530, a selective Src kinase
inhibitor
Recurrent osteosarcoma localized to the
lung
SARC012
IMC-A12 and doxorubicin hydrochloride Patients with unresectable, locally advanced,
or metastatic soft tissue sarcoma
NCT00720174
IMC-A12
Young patients with relapsed or refractory
ewing sarcoma/peripheral primitive
neuroectodermal tumor or other solid
tumor
NCT00609141
R1507 Patients with recurrent or refractory
sarcoma
NCT00642941
CP751871 ﬁgitumumab combined with
pegvisomant Advanced solid tumors NCT00976508
Bevacizumab and AZD2171
Patients with metastatic or unresectable
solid tumor, lymphoma, intracranial
glioblastoma, gliosarcoma, or anaplastic
astrocytoma
NCT00458731
Cediranib (tentative trade name recentin), also
known as AZD2171
Young patients with refractory or recurrent
solid tumors or acute myeloid leukemia
NCT00354848
Temozolomide, cixutumumab, and
combination chemotherapy
Treating patients with metastatic
rhabdomyosarcoma
NCT01055314
Cixutumumab IMC A12 Treating patients with relapsed or refractory
solid tumors
NCT00831844
Cixutumumab and temsirolimus
Treating young patients with solid tumors
that have recurred or not responded to
treatment
NCT00880282
A study of SCH 717454 in combination with
diﬀerent treatment regimens
Pediatric subjects with advanced solid
tumors (Study P05883)
NCT00960063
SCH 717454 in combination with diﬀerent
treatment regimens Advanced solid tumors (P04722) NCT00954512
Temsirolimus and valproic acid
Treating young patients with relapsed
neuroblastoma, bone sarcoma, or soft tissue
sarcoma
NCT01204450
Temsirolimus, irinotecan hydrochloride, and
temozolomide
Treating young patients with relapsed or
refractory solid tumors
NCT01141244
PCI-24781 in combination with doxorubicin Treat sarcoma NCT01027910
Angiogenesis inhibitor SU5416 Treating patients with soft tissue sarcoma NCT00023738
Sorafenib and bevacizumab Treating patients with refractory, metastatic,
or unresectable solid tumors
NCT00098592
Sunitinib Treating patients with metastatic, locally
advanced, or locally recurrent sarcomas
NCT00474994
Radiation therapy with or without SU5416
(TK inhibitor antiangiogenesis compound) Treating patients with soft tissue sarcoma NCT00023725
Phase II study of doxorubicin and
bevacizumab (anti-VEFG monoclonal
antibody, NSC 704865)
Patients with advanced or metastatic
soft-tissue sarcoma
NCT00052390
Phase I/II study of gemcitabine, docetaxel, and
bevacizumab Patients with soft tissue sarcoma NCT00276055
Phase II study of neoadjuvant bevacizumab
and radiation therapy Resectable soft tissue sarcomas NCT00356031
∗Source: http://www.clinicaltrials.gov/.Sarcoma 7
into a chronic disease? Genomic plasticity is the hallmark
of cancer, thus one would anticipate evolution of cancer
cells that circumvent such treatments. Thus, the role of
antiangiogenic therapy is most likely in the context of
conventional chemotherapy, or in combination with other
signaling inhibitors. Whether addition of small molecule
inhibitors of angiogenesis will permit the maintenance of
dose intensity of current cytotoxic regimens remains to
be determined. For example, results from adult clinical
trials suggest that dose intensity of cytotoxic agents or the
dose of cediranib has to be reduced [99]. Available results
from trials of IGF-1R-targeted antibodies suggest a low
response rate even in Ewing sarcoma, suggesting that these
agents poorly suppress tumor cell proliferation or tumor
cells are able to circumvent the antiangiogenic activity of
these antibodies. One aspect of antiangiogenic therapy that
holds some promise is the eﬀect of vascular normalization
that allows reoxygenation [100, 101]( a n dh e n c ei n c r e a s e d
radiationsensitivity)orincreaseduptakeofdrugsintotumor
tissue [102–104].
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